**Financial Highlights:** In Q3 FY25, SeQuent Scientific reported revenues of ₹3,908 mn, reflecting an 18.7% year-on-year growth, driven by a strong performance in both Formulations and API segments.

The gross margin improved to 48.2%, aided by pricing strategies and operational efficiencies.

EBITDA (pre-ESOP) stood at ₹494 mn, a substantial 63.8% increase year-on-year, highlighting robust profitability.

For the nine months ending December 2024, total revenues reached ₹11,497 mn, marking a 14.0% rise. **Strategic Initiatives and Growth Drivers:** The integration with Viyash Life Sciences is progressing, with key approvals underway and expected completion by December 2025. Viyash's performance remains strong, showing a 19% revenue growth and significant EBITDA margin improvement. **Business Developments:** The company's facilities in Turkey and Mahad have received crucial global approvals, enhancing their market readiness.

Notably, strong growth in the emerging markets, particularly Turkey, is positioned as a key contributor to future revenue streams. **Market Position and Competitive Advantage:** SeQuent continues to strengthen its global pharmaceutical platform, leveraging synergies with Viyash to enhance R&D capabilities and market penetration across diverse geographies. **Investor Implications:** Investors may perceive positive outlooks due to strong year-on-year financial performance, a strategic merger that promises enhanced growth avenues, and improved operational efficiencies that could lead to sustained profitability in the coming quarters.